Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL1412252 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL22686437 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL42945 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL29587574 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL1291555 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL23012792 | 0.94 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL21555662 | 0.94 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL9171055 | 0.94 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL20668544 | 0.94 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL1155635 | 0.94 | CA4 (0.89) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122035808-A | Layered tin pyrophosphate composite anode material and preparation method thereof | 辽宁石油化工大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260102523-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | JUBILANT DRAXIMAGE INC (CA) | 2026-04-16 | — | — | US | claimed |
| EP-4037638-B1 | ORAL CARE COMPOSITIONS COMPRISING STANNOUS ION SOURCE, NEUTRAL AMINO ACID, AND POLYPHOSPHATE | PROCTER & GAMBLE (US) | 2026-04-01 | — | — | EP | claimed |
| EP-3773453-B1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | PROCTER & GAMBLE (US) | 2026-04-01 | — | — | EP | claimed |
| EP-4687816-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | The Procter & Gamble Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4687817-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | The Procter & Gamble Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4687815-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | The Procter & Gamble Company (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260034041-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | PROCTER & GAMBLE (US) | 2026-02-05 | — | — | US | claimed |
| US-20260027028-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | PROCTER & GAMBLE (US) | 2026-01-29 | — | — | US | claimed |
| US-20260027029-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | PROCTER & GAMBLE (US) | 2026-01-29 | — | — | US | claimed |
| CN-1007256-B | TIN OR BISMUTH COORDIRATED CATALYST AND THE RELEVANT COATINGS TRIGGING-SOLIDIFYING | JARSELAN OIL CO (US) | 1990-03-21 | — | — | CN | claimed |
| US-4788083-A | POLYURETHANES, POT LIFE | ASHLAND OIL, INC. (US) | 1988-11-29 | — | — | US | claimed |
| US-4783434-A | Process for loading a carrier with a catalytically active material or with a precursor of a catalytically active material, and the catalyst produced by said process | THE DOW CHEMICAL COMPANY (US) | 1988-11-08 | — | — | US | claimed |
| US-4707353-A | Radiographic imaging agents | MALLINCKRODT, INC. (US) | 1987-11-17 | — | — | US | claimed |
| CN-87102399-A | Tin or bismuth coordination catalyst and relative coating cause and solidify | — | 1987-10-07 | — | — | CN | claimed |
| EP-0169232-A1 | Composition for technetium-99m labelling of proteinaceous material. | INST ENERGITEKNIK (NO) | 1986-01-29 | — | — | EP | claimed |
| WO-1985003231-A1 | TECHNETIUM-99m COMPOSITION FOR LABELLING PROTEINACEOUS MATERIAL AND METHOD | INSTITUTT FOR ENERGITEKNIKK (NO) | 1985-08-01 | — | — | WO | claimed |
| US-4510125-A | CONTACTING ASCORBATE, GENTISATE, OR REDUCTATE STABILIZER WITH TIN | MALLINCKRODT, INC. (US) | 1985-04-09 | — | — | US | claimed |
| EP-0111414-A2 | Radiographic imaging agents | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1984-06-20 | — | — | EP | claimed |
| US-3988429-A | Kit for the rapid preparation of 99m Tc red blood cells | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES ENERGY RESEARCH AND DEVELOPMENT ADMINISTRATION (US) | 1976-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027028-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | TAS2R40, MUC1, TAS1R1 | CA4 489/4885ALDH1A1 4374/4885CASP1 1367/4885 |
| US-20260034041-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | KCNN1, TAS1R1, MUC1 | CA4 994/4885ALDH1A1 4291/4885CASP1 817/4885 |
| US-20260027029-A1 | ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTH | CACNA1H, KCNN1, TAS2R40 | CA4 977/4885ALDH1A1 4596/4885CASP1 992/4885 |
| US-20260102523-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TREH, CD68, THPO | CA4 60/4885ALDH1A1 4433/4885CASP1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.